(2-氨基-苯基)-乙酸甲酯盐酸盐 | 49851-36-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-氨基-苯基)-乙酸甲酯盐酸盐
• 英文名称: methyl 2-(2-aminophenyl)acetate hydrochloride
• 英文别名: Hydron; methyl 2-(2-aminophenyl)ethanoate; chloride；hydron;methyl 2-(2-aminophenyl)acetate;chloride
• CAS: 49851-36-7
• 化学式: C₉H₁₁NO₂*ClH
• mdl: MFCD07371496
• 分子量: 201.653
• InChiKey: OZMUKUBEEKGADM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  (2-氨基-苯基)-乙酸甲酯盐酸盐 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 methyl 2-(2-amino-5-bromophenyl)acetate
  参考文献：
  名称：

  [EN] AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF
  [FR] DÉRIVÉS D'AMINOMÉTHYL-BIARYL EN TANT QU'INHIBITEURS DU FACTEUR D DU COMPLÉMENT ET LEURS UTILISATIONS

  摘要：

  本发明提供了一种公式(I)的化合物，一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。

  公开号：

  WO2015009977A1

文献信息

• [EN] AMIDOMETHYL-BIARYL DERIVATIVES COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMINOMÉTHYL-BIARYLE EN TANT QU'INHIBITEURS DU FACTEUR D DU COMPLÉMENT ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2016088082A1

  公开（公告）日：2016-06-09

  The present invention provides a compound of formula (I): (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式(I)的化合物：(I)一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
  申请人：Jaehne Gerhard

  公开号：US20110112097A1

  公开（公告）日：2011-05-12

  The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

  该发明涉及式(I)的化合物，其中基团R和R'、A、D、E、G、L、p以及R1到R10具有所述含义，以及它们的生理相容盐。所述化合物适用于作为抗肥胖药物。
• Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
  申请人：BELANGER David B.

  公开号：US20160145247A1

  公开（公告）日：2016-05-26

  The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式（I）的化合物，一种制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合物和制药组合物。
• Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
  作者：Rajeshri G. Karki、James Powers、Nello Mainolfi、Karen Anderson、David B. Belanger、Donglei Liu、Nan Ji、Keith Jendza、Christine F. Gelin、Aengus Mac Sweeney、Catherine Solovay、Omar Delgado、Maura Crowley、Sha-Mei Liao、Upendra A. Argikar、Stefanie Flohr、Laura R. La Bonte、Edwige L. Lorthiois、Anna Vulpetti、Ann Brown、Debby Long、Melissa Prentiss、Nathalie Gradoux、Andrea de Erkenez、Frederic Cumin、Christopher Adams、Bruce Jaffee、Muneto Mogi

  DOI：10.1021/acs.jmedchem.9b00271

  日期：2019.5.9

  Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system. Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria. Previously, we have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (1 and 2) binding to the open active conformation of FD. In continuation of our drug discovery program, we designed compounds applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases. We report herein the design, synthesis, and medicinal chemistry optimization of the benzylamine series culminating in the discovery of 12, an orally bioavailable and selective FD inhibitor. 12 demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
• Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent
  作者：Masahide Odan、Natsuki Ishizuka、Yoshiharu Hiramatsu、Masanao Inagaki、Hiroshi Hashizume、Yasuhiko Fujii、Susumu Mitsumori、Yasuhide Morioka、Masahiko Soga、Masashi Deguchi、Kiyoshi Yasui、Akinori Arimura

  DOI：10.1016/j.bmcl.2012.02.050

  日期：2012.4

  The optimization of a series of 3-carbamoyl 2-pyridone derivatives as CB agonists is reported. These efforts resulted in the discovery of 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid (21), a potent dual CB1/CB2 agonist without CNS side effects induced by CB1 receptor activation. It exhibited strong inhibition of scratching as a 1.0% acetone solution in the pruritic model. (C) 2012 Elsevier Ltd. All rights reserved.